AI assistant
MYRIAD GENETICS INC — Director's Dealing 2015
Jan 6, 2015
32566_dirs_2015-01-06_cb559a3c-c521-4e81-a1b8-61c71717d181.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2015-01-02
Reporting Person: Tobin Bernard (President Crescendo BioScience)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-02 | Common Stock | A | 12000.0 | $0.0 | Acquired | 12000 | Direct |
| 2015-01-02 | Common Stock | A | 28000.0 | $0.0 | Acquired | 40000 | Direct |
| 2015-01-02 | Common Stock | F | 4720.0 | $34.61 | Disposed | 35280 | Direct |
Footnotes
F1: Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Restricted stock units granted and immediately vested upon employment.
F2: Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% per year over a four-year period on each anniversary of the date of grant.